Pharmacological characterization of TA-0201, an endothelin receptor antagonist, with recombinant and human prostate endothelin receptors

Author： Takahashi M. Taniguchi T. Tanaka T. Kanamaru H. Okada K. Muramatsu I.

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.467, Iss.1, 2003-04, pp. : 185-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of the endothelin ET A receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats

By Itoh H. Yokochi A. Yamauchi-Kohno R. Maruyama K.

European Journal of Pharmacology, Vol. 376, Iss. 3, 1999-07 ,pp. : 233-238

Elsevier

Access to resources Recommend Favorite

Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET A receptor antagonist

By Yuyama H. Sanagi M. Koakutsu A. Mori M. Fujimori A. Harada H. Sudoh K. Miyata K.

European Journal of Pharmacology, Vol. 478, Iss. 1, 2003-09 ,pp. : 61-71

Elsevier

Access to resources Recommend Favorite

Bosentan: a dual endothelin receptor antagonist

By Roux Sébastien Rubin Lewis J

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 7, 2002-07 ,pp. : 991-1002

Informa Healthcare

Access to resources Recommend Favorite

Antagonist activity of [Thr 18 , -methylleucine 19 ]endothelin-1 in human endothelin receptors

By Masuda Y. Sugo T. Kikuchi T. Satoh M. Fujisawa Y. Itoh Y. Wakimasu M. Ohtaki T.

European Journal of Pharmacology, Vol. 325, Iss. 2, 1997-05 ,pp. : 263-270

Elsevier

Access to resources Recommend Favorite

Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

By Jasper Dingemanse Paul L.M. van Giersbergen

Clinical Pharmacokinetics, Vol. 43, Iss. 15, 2004-01 ,pp. : 1089-1115

Adis International

Access to resources Recommend Favorite